Breast Cancer Study Aims to Unlock the Doors of Individualized Patient Care With Big Data

National Comprehensive Cancer Network reported that an unprecedented approach to clinical research, documented in the January issue of JNCCN — Journal of the National Comprehensive Cancer Network, brought together 32 researchers from 14 different institutions, including community and academic cancer centers, universities, and biotechnology and data sciences companies, to identify potential interventions for a patient with metastatic triple-negative breast cancer (TNBC) — an especially aggressive subset of breast cancer that is widely considered to be incurable.
According to the research:

The Intensive Trial of OMics in Cancer (ITOMIC) deeply characterizes and tracks the molecular features of a patient’s tumor, aggregates experts to generate hypotheses regarding treatments that are predicted to be beneficial, allows these predictions to be tested in the patient, and learns from these experiences to help future patients. This first report from ITOMIC describes a patient with triple-negative breast cancer metastatic to bone, who had markedly elevated circulating tumor cells (CTCs) that were monitored 48 times over nine months.

Click here to view the full release.